Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Roswell Biotechnologies
AddedFeb 17, 2024
UpdatedJun 18, 2026
Roswell Biotechnologies

Roswell Biotechnologies

Roswell Biotechnologies digitizes biology using molecular electronics for disease diagnosis and treatment.

Founded
2014
Overview
Compare
Fundraising
Employees
Website

Roswell Biotechnologies, founded with a mission to digitize biology, leverages molecular electronics to advance disease diagnosis and treatment. The company has pioneered the Roswell ME Chip, the first molecular electronics chip that integrates single molecules into standard semiconductor technology. This innovation is aimed at applications in basic, discovery, and translational research, molecular diagnostics, genome sequencing, and other applied markets.

Notable affiliated individuals and investors include leading experts in molecular electronics and biotechnology. Roswell Biotechnologies has achieved significant milestones, including the demonstration of the first scalable molecular electronics chip in a peer-reviewed paper. The company's groundbreaking work is poised to revolutionize the fields of diagnostics and personalized medicine, making a substantial impact on healthcare and scientific research.

Roswell Biotechnologies - Similar Companies

NorthShore Bio logo

NorthShore Bio

Ontera logo

Ontera

ontera.bio

Nanopath logo

Nanopath

nanopathdx.com

Electronic Biosciences logo

Electronic Biosciences

electronicbio.com

Molecular Biometrics logo

Molecular Biometrics

Biorosa Technologies logo

Biorosa Technologies

biorosa.com

Molecular Assemblies logo

Molecular Assemblies

BridGene Biosciences logo

BridGene Biosciences

Diagnostic Biochips logo

Diagnostic Biochips

Inherent Biosciences logo

Inherent Biosciences

inherentbio.com

Plasmonix logo

Plasmonix

NanoMosaic logo

NanoMosaic

Grip Molecular Technologies logo

Grip Molecular Technologies

gripmolecular.com

Complete Omics logo

Complete Omics

completeomics.com

Gemelli Biotech logo

Gemelli Biotech

gemellibiotech.com

Roswell Biotechnologies - Quick Facts

Who are Roswell Biotechnologies' competitors?

Companies similar to Roswell Biotechnologies include NorthShore Bio, Ontera, Nanopath and Electronic Biosciences.

When was Roswell Biotechnologies founded?

Roswell Biotechnologies was founded in 2014.

When was Roswell Biotechnologies' last funding round?

Roswell Biotechnologies' most recent funding round was for $32M (USD) in January 2019.

How much has Roswell Biotechnologies raised to-date?

As of Jan 3, 2019, Roswell Biotechnologies has raised a total of $37M (USD).

How many employees does Roswell Biotechnologies have?

Roswell Biotechnologies has 42 employees as of Feb 4, 2024.

Roswell Biotechnologies - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
  • Data
Geographic Exposure
  • Global
Revenue
  • Recurring
Main Product
  • Molecular Electronics
Tags
  • Hardware
  • Platform
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software